{"entity":{"id":"nct07051785","kind":"trial","name":"Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer","aka":["ARK"],"tldr":"A phase 2 trial of fruquintinib, capecitabine and bevacizumab (glioblastoma use) in colorectal cancer, run by Liu Huang, not yet recruiting.","summary":"Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer is a phase 2, randomised interventional study registered as NCT07051785 by Liu Huang, with a registry enrolment figure of 68 participants, started 2025-07-07 and due to reach its primary completion in 2027-07-06. Interventions recorded: Fruquintinib+Irinotecan Liposome+Capecitabine; Bevacizumab+Irinotecan Liposome+Capecitabine. Conditions listed: Colorectal Cancer (CRC). Primary outcome: Progression-free Survival (PFS). Colorectal eligibility wording from the registry: \"Patients with metastatic colorectal adenocarcinoma confirmed by pathology or histology;\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07051785","url":"https://clinicaltrials.gov/study/NCT07051785"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["antiangiogenic","cytotoxic-chemotherapy","kinase-inhibitors"],"targets":[],"drugs":["fruquintinib","capecitabine","bevacizumab-glioma"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07051785","phase":"2","setting":"Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer：A Multicenter Randomized Controlled Trial","sponsor":"Liu Huang","enrolled":68,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07051785/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"fruquintinib","kind":"drug","name":"Fruquintinib","route":"/drugs/fruquintinib/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}